On October 11, 2022 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, reported the award of two additional Small Business Innovation Research (SBIR) phase II grants totaling $4 million (Press release, Viewpoint Molecular Targeting, OCT 11, 2022, https://viewpointmt.com/viewpoint-molecular-targeting-announces-two-new-grant-awards-of-2-million-each/ [SID1234621891]). The first award of $2 million is intended to assess image-guided dosimetry-based alpha particle therapy for neuroblastoma. The second award of $2 million was awarded for the purpose of combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma. These recently awarded grants bring the total amount of SBIR awards of approximately $17 million through October 2022 from the National Institutes of Health (NIH) and National Cancer Institute (NCI) to our principal collaborators at the University of Iowa, including Michael K. Schultz, PhD, our co-founder and Chief Scientific Officer, and Frances L. Johnson, MD, our co-founder and Chief Operating Officer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are grateful that our science has been recognized since the Company’s inception with such significant support from the NIH and NCI to support our targeted alpha therapy development activities," said Thijs Spoor, CEO of Viewpoint Molecular Targeting.
Dr. Schultz commented, "as our researchers continue to expand the potential applications of targeted alpha therapies generally, and the compelling science behind Pb-212 specifically, we continue to be excited by the transformational nature we think our emerging discoveries will have on the lives of cancer patients."